ImmuCell Corporation Investor Presentation August 2025 (Nasdaq: ICCC) 2 Table of Contents | 1) | Company Overview and Strategic Opportunity..…….……..…………………………………………………….….… 4-27 | | --- | --- | | 2) | Testimonials………………………………………………………………….……..…….…………………………………….……….…28-32 | | 3) | Financial Review(1).………………..….……..……………………………..……………………………………………..… 33-39 | | 4) | Other Information..……………...………...………………………………………….……………………………...……….…….40-52 | (1)Detailed financial reports, summary press releases and conference ...

Core Insights - ImmuCell Corporation has initiated a search for a new President and CEO as current CEO Michael F. Brigham plans to retire by early 2026 after serving since 2000 [1][2][3] - The company aims to identify a suitable successor by the end of the year, with Brigham committed to assisting in the transition [2][3] Company Overview - ImmuCell Corporation focuses on developing, manufacturing, and marketing products that enhance the health and productivity of dairy and beef cattle [1][3] - The company’s notable products include First Defense®, which provides Immediate Immunity™ to newborn calves, and Re-Tain®, a treatment for subclinical mastitis in dairy cows [3]

Company Overview and Strategy - ImmuCell Corporation focuses on growth in First Defense product line sales and aims to revolutionize subclinical mastitis treatment with Re-Tain[10] - The company addresses the $2 billion annual economic harm to the dairy industry caused by mastitis without traditional antibiotics, using Re-Tain (subject to FDA approval)[10, 53] - Three critical action items include growing First Defense sales, achieving FDA approval for Re-Tain, and proving market acceptance of Re-Tain with $10 million annual production capacity[18] - The company completed an investment to increase First Defense production capacity to over $30 million in annual sales value[29, 49] Product Lines and Market Opportunities - The U S market opportunity for calf-level products to prevent scours is approximately $31 1 million annually[32, 51] - The U S market opportunity for calf-level and dam-level vaccine products used to prevent scours is estimated at $81 8 million annually[32, 51] - Mastitis causes an estimated $2 billion in economic loss to the dairy industry each year[33, 52] Financial Performance - As of March 31, 2025, the company's cash and cash equivalents were $4 6 million, and total assets were $45 6 million[83] - For the three-month period ended March 31, 2025, product sales were $8 1 million, with a gross margin of 42%[87] - The company's total project cost for First Defense is estimated at $14 177 million, and for Re-Tain, it's $5 382 million[90]

Core Viewpoint - ImmuCell Corporation has appointed Timothy C. Fiori as Chief Financial Officer, bringing significant experience to the company during a crucial phase of its development [1][2][3]. Company Overview - ImmuCell Corporation focuses on developing, manufacturing, and marketing products that enhance the health and productivity of dairy and beef cattle [4]. - The company offers First Defense®, which provides Immediate Immunity™ to newborn calves, and is nearing the completion of Re-Tain®, a treatment for subclinical mastitis in dairy cows that avoids traditional antibiotic restrictions [4]. Leadership Changes - Timothy C. Fiori has approximately 24 years of finance and commercial operating experience from IDEXX Laboratories [2]. - Fiori expressed enthusiasm about joining ImmuCell and contributing to the company's growth, highlighting the potential of its product portfolio [3]. - Michael F. Brigham, President and CEO, emphasized that Fiori's experience will be instrumental in improving financial systems and operational efficiencies [3].